WallStSmart

Abbott Laboratories (ABT)vsLucid Diagnostics Inc (LUCD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 879020% more annual revenue ($45.13B vs $5.13M). ABT leads profitability with a 13.9% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LUCD

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 3.5
Piotroski: 4/9Altman Z: -12.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for LUCD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

LUCD1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
51.7%10/10

Revenue surging 51.7% year-over-year

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

LUCD4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$187.53M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-711.0%2/10

ROE of -711.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : LUCD

The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 51.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : LUCD

The primary concerns for LUCD are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 6.70 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while LUCD is a hypergrowth play — different risk/reward profiles.

LUCD carries more volatility with a beta of 1.08 — expect wider price swings.

LUCD is growing revenue faster at 51.7% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Lucid Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?